Overview

Liver Transplantation With Tregs at UCSF

Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Immune Tolerance Network (ITN)
PPD
Rho Federal Systems Division, Inc.
Treatments:
Cyclophosphamide
Everolimus
Mesna
Sirolimus